More for AtCor
Thursday, 24 July, 2008
AtCor Medical [ASX: ACG] has reached new supply agreements for its SphygmoCor blood-pressure measurement systems.
The contracts are worth at least a combined $1.66 million. AtCor has secured $2.8 million worth of contracts in the past 60 days.
SphygmoCor is a blood pressure monitoring system that identifies the effects of reflected blood pressure in the central aortic pressure wave.
The company has sold over 1,400 SphygmoCors to medical institutions and research institutions conducting clinical trials, as the device can be used to measure the effects of medication on central blood pressure.
Indigenous-led initiative to resurrect the South Island Giant Moa
New Zealand's Ngāi Tahu Research Centre has partnered with Colossal Biosciences and Sir Peter...
Abnormal brain protein targeted in Parkinson's study
Researchers have identified a new brain protein involved in the development of Parkinson's...
Epilepsy disease model treated in a laboratory dish
A research team has used an epilepsy-like disease model in a laboratory dish to demonstrate that...
